MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
84.50
-1.09
-1.27%
After Hours: 84.50 0 0.00% 17:41 05/14 EDT
OPEN
85.59
PREV CLOSE
85.59
HIGH
86.70
LOW
83.32
VOLUME
327.46K
TURNOVER
--
52 WEEK HIGH
103.00
52 WEEK LOW
28.06
MARKET CAP
6.95B
P/E (TTM)
-23.6708
1D
5D
1M
3M
1Y
5Y
1D
Kymera Therapeutics director Elena Ridloff disposes of 3,000 shares for $261,000
PUBT · 3d ago
Weekly Report: what happened at KYMR last week (0504-0508)?
Weekly Report · 3d ago
Kymera Therapeutics initiated with a Buy at Canaccord
TipRanks · 05/07 10:32
AMD upgraded, Reddit downgraded: Wall Street’s top analyst calls
TipRanks · 05/07 04:00
Kymera Therapeutics Price Target Announced at $106.00/Share by Canaccord Genuity
Dow Jones · 05/06 17:54
Kymera Therapeutics Initiated at Buy by Canaccord Genuity
Dow Jones · 05/06 17:54
Canaccord Genuity Initiates Coverage On Kymera Therapeutics with Buy Rating, Announces Price Target of $106
Benzinga · 05/06 17:45
Kymera Therapeutics to join Bank of America Healthcare Conference fireside chat
PUBT · 05/06 11:09
More
About KYMR
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system with a primary focus on immunology. The Company's targeted protein degradation (TPD) platform, which is a small molecule therapeutic modality that engages the body’s natural cellular recycling system to selectively eliminate disease-causing proteins. Its immunology programs target STAT6, IRF5 and IRAK4, each of which addresses targets within validated pathways, providing the opportunity to treat a broad range of diseases. It is developing KT-621 as part of its STAT6 program, which is being evaluated in a Phase I clinical trial in healthy volunteers. It is developing KT-579, which is an investigational, first-in-class, oral IRF5, degrader being developed for the treatment of rheumatic and autoimmune diseases.

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.